SIR -Genetic factors are thought to contribute to susceptibility to develop tardive dyskinesia (TD), a major side effect of chronic antipsychotic drug treatment. As the 5-HT2C receptor is involved in motor function including the production of dyskinesias, and polymorphisms of the 5HT2C receptor promotor region with different promotor activities have been identified, 1 we assessed the association with TD of two of these polymorphisms in Chinese schizophrenic patients.
Concordance for the presence or absence of TD between first-degree relatives receiving chronic neuroleptic treatment indicates the importance of genetic factors in this side effect. 2 Pharmacogenetic association studies of TD have implicated several genes including, for example, those for the dopamine D3 receptor, 3, 4 
CYP2D6
5 and 5-HT2A receptor. 6 A further candidate gene is the 5-HT2C receptor. 5-HT2C antagonists reduce catalepsy induced by haloperidol 7 and the orofacial dyskinesias elicited by 5-HT agonists injected into the rat subthalamic nucleus. 8 One previous genetic study has reported a significant excess of the 5-HT2C 23Ser allele in female patients with orofacial TD. However, the scarcity of the 23Ser variant in a Chinese population 9 suggests it is unlikely to contribute substantially to pharmacogenetic differences in this ethnic group.
Recently, the promoter region of the 5-HT2C receptor gene, located on the X chromosome, was found to exhibit four polymorphisms that can alter expression levels of the 5-HT2C receptor and contribute to pathophysiological differences. 1 These observations prompted us to investigate the association with TD of the −759C/T and −697G/C polymorphisms in the promoter region of the 5-HT2C receptor gene in hospitalized male Chinese Han patients meeting DSM-IV criteria for schizophrenia. Patients (n = 326) treated with antipsychotic agents for longer than 8 years were assessed for TD using the Abnormal Involuntary Movement Scale (AIMS) according to research diagnostic criteria. 10 The final sample comprised 42 patients with persistent TD and 50 patients consistently without dyskinesias. The TD group had a mean AIMS score of 6.5 (±1.8 SD); apart from the presence or absence of dyskinesias, the clinical features between the TD and non-TD groups were closely matched with no significant differences in age (56.1 ± 10.4 years and 54.9 ± 7.4 years, mean ± SD, respectively), age of onset, length of treatment, total or current dosage or Brief Psychiatric Rating Scale (BPRS) score. We observed a point prevalence for TD of 15%, and a prevalence of 13% for persistent TD, in this population of patients with schizophrenia. The project had approval of the local ethical committee, and written informed consent was obtained from all participants.
A fragment of genomic DNA extracted from blood and including the −759 and −697 polymorphic loci of the 5-HT2C receptor gene regulatory region (Genbank accession number U49648) was amplified by PCR as previously described. 1 The resulting PCR product was digested with AciI according to the manufacturer's recommendations (New England Biolabs, UK), and digestion products analysed following 3% agarose gel electrophoresis. Allele frequencies in the TD and non-TD groups for −759C/T and −697G/C polymorphisms in the 5-HT2C receptor gene are shown in Table 1 . Qualitatively, the results are consistent with Yuan et al; 1 the −759T and −697C variants were closely linked with no cases of a −759T/−697G haplotype.
There was a significant excess of the −697 variant in patients with TD over those without (OR = 2.80, CI = 1.08-7.27). Differences in the frequencies of the −759 variant and of the haplotypes did not reach significance. There were no significant differences in any clinical demographic characteristics or BPRS scores between wild-type and variant −759 or −697 forms in all patients or within the TD group.
Thus we have identified an association of a functional polymorphism in the promoter region of the 5-HT2C-receptor gene with TD in male Chinese schizophrenic patients. The persistent nature of the disorder in our TD group, and the matched comparison group of patients without dyskinesias, provides an optimal population in which to identify genetic risk factors associated with TD.
Although the exact functional importance of the −697 G to C substitution is unclear, its contribution to an increase in receptor expression 1 may lead to a hyperfunction of 5-HT neurotransmission through the 5-HT2C receptor, resulting in an elevated susceptibility to dyskinesia.
No occurrence of the glutamate transporter EAAT2 A206G polymorphism in schizophrenic subjects
Molecular Psychiatry (2002) 7, 671-672. doi:10.1038/ sj.mp.4001055 SIR -Glutamate is the most important excitatory neurotransmitter in the brain. However, glutamate can also act as a neurotoxin, and its uptake and metabolization is of critical importance. Five types of high-affinity glutamate transporters (ie GLT1, EAAC1, GLAST, EAAT4 and EAAT5) have been cloned since 1992. They regulate levels of extracellular glutamate in the central nervous system and differ both in their expression and uptake ability. 1 Evidence suggests that the reuptake of synaptically released glutamate is much more efficient within astrocytes than within neurons. 2 In fact, while EAAC1 and EAAT4 are expressed in neurons, the greatest part of glutamate uptake in the brain is carried out by two astroglial transporters GLT1 and GLAST (EAAT2 and EAAT1 in humans, respectively). 1 Recent studies have suggested that abnormalities and dysfunction in the uptake and metabolism of glutamate could be involved in some neuropsychiatric disorders. In particular, defective glutamate transport may play a critical role in the neurotoxicity associated with ischaemia, epilepsy, neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). 3 On the other hand, an excessive uptake, leading to a relative glutamatergic hypofunction, is suspected to be involved in psychiatric disorders including schizophrenia. Very recent findings, both pharmacological and molecular, seem to support this hypothesis, as well as the possible candidate role for the gene encoding EAAT2. 4, 5 Thus, we studied an A→G transition in codon 206 of the exon 5 of this gene, causing a substitution of serine for asparagine, 6 in a sample of schizophrenics of Italian descent. This change introduces a new HhaI site in the mutant allele and may be potentially of functional significance as asparagine 206 is a putative glycosylation site of the EAAT2 protein. 7 Interestingly, disruption of putative N-glycosylation sites seems to affect transport activity of the neuronal glycine transporter GLYT2 8 and GABA transporter GAT1. 9 One hundred and twenty-four schizophrenic patients, and fifty healthy control subjects, recruited at the IRCCS H San Raffaele, DSNP and IRCCS San Giovanni di Dio, FBF, were included in the study. Senior psychiatrists diagnosed all patients according to DSM-IV criteria and all the subjects gave their informed consent.
Patients and controls were genotyped using a PCRbased technique, followed by both enzymatic digestion and denaturing gradient gel electrophoresis technique (DGGE).
